Wells Fargo & Company Vyne Therapeutics Inc. Transaction History

Wells Fargo & Company

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$0.12 - $4.91 $118 - $4,860	-990 Reduced 38.75%	1,565 $0
Q3 2022 Nov 14, 2022	BUY	$0.24 - $4.27 $250 - $4,457	1,044 Added 69.09%	2,555 $0
Q2 2022 Aug 12, 2022	BUY	$0.37 - $0.71 $18 - $36	51 Added 3.49%	1,511 $0
Q1 2022 May 16, 2022	BUY	$0.5 - $1.15 $0 - $1	1 Added 0.07%	1,460 $1,000
Q4 2021 Feb 14, 2022	BUY	$0.91 - $1.5 $1,327 - $2,188	1,459 New	1,459 $1,000
Q2 2021 Aug 16, 2021	SELL	$3.24 - $6.92 $25,139 - $53,692	-7,759 Closed	0 $0
Q1 2021 May 13, 2021	BUY	$6.34 - $12.68 $49,192 - $98,384	7,759 New	7,759 $53,000

36.5K

Ticker VYNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,005,600
Market Cap $176M
Description
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, whi...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.